Is Alpha-lipoic acid (ALA) worth it?
ALA has a real but narrow diabetic-neuropathy signal; the broad blood-sugar marketing is weaker. If it earns a slot, it is as simple 600 mg ALA for neuropathy symptom support with glucose monitoring, not as a replacement for diabetes care.
The call
The strongest clinical case is diabetic peripheral neuropathy, especially symptom scores in short trials. A meta-analysis found a clearer effect for intravenous 600 mg/day over three weeks, while oral ALA above 600 mg/day showed statistical improvement whose clinical importance was uncertain. AAFP's evidence review reaches the same practical conclusion: IV ALA has short-term symptom evidence, but oral ALA is less convincing and long-term treatment evidence is missing. For blood sugar, the claim should stay secondary and monitored; ALA is not a reliable stand-alone glucose-control strategy.
Safety
ALA may lower blood glucose, so people using insulin, sulfonylureas, GLP-1 drugs, metformin, or other glucose-lowering medication should monitor for hypoglycemia and use clinician guidance. Common side effects include nausea, reflux, abdominal discomfort, headache, rash, and dizziness, with higher doses more likely to cause gastrointestinal problems. Rare reports link ALA supplements to insulin autoimmune syndrome with spontaneous hypoglycemia, especially in genetically susceptible people. Avoid routine use during pregnancy or breastfeeding unless medically supervised, and use caution with thyroid medication, heavy alcohol use, thiamine deficiency risk, liver disease, kidney disease, or planned surgery.
Dose that matters: 600 mg/day oral alpha-lipoic acid, preferably away from meals for absorption; reassess after 8-12 weeks. Intravenous 600 mg/day protocols studied for diabetic neuropathy are clinician-administered therapy, not a supplement routine.
Sources
Tier 1 · evidence synthesis · Reviewed by the Stack-kit desk